GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Heterogeneous human epidermal growth factor receptor 2 (HER2) overexpression in gastric cancer may lead to a misdiagnosis of HER2 status. Accurate assessment of HER2 status is essential for optimal treatment as novel HER2-directed agents are being investigated in various clinical settings. We evaluated the usefulness of HER2 re-assessment following progression on first-line treatment in initially HER2-negative advanced gastric cancer (AGC) patients.Materials and Methods We enrolled 177 patients with baseline HER2-negative AGC and performed HER2 re-assessment after progression on first-line treatment from February 2012 to June 2016 at Asan Medical Center, Seoul, Korea. The re-assessed HER2 status was analyzed with baseline HER2 status and clinical characteristics.Results The median age was 54 years (range, 24 to 80 years), and 123 patients (69.5%) were men. Seven patients (4.0%) were HER2-positive on the re-assessment. Patients with baseline HER2 negativity confirmed by a single test (n=100) had a higher HER2-positive re-assessment rate compared to those who had repeated baseline testing (n=77) (5.0% vs. 2.6%). Among the patients with single baseline HER2 testing, the rate was higher in patients with baseline HER2 immunohistochemistry (IHC) 1+ compared to those with IHC 0 (13.4% vs. 3.6%).Conclusion Overall, 4.0% of patients with baseline HER2-negative AGC were HER2-positive on re-assessment, and the HER2-positive re-assessment rate was higher among patients who had a single test at baseline. HER2 re assessment may be considered for initially HER2-negative patients to determine their eligibility for HER2-directed therapy, particularly if their HER2 negativity was determined by a single test, especially if they had a single baseline HER2 IHC 1+ test.
Abstract
Purpose Heterogeneous human epidermal growth factor receptor 2 (HER2) overexpression in gastric cancer may lead to a misdiagnosis of HER2 status. Accurate assessment of HER2 status is essential for optimal treatment as novel HER2-directed agents are being investigated in various clinical settings. We evaluated the usefulness of HER2 re-assessment following progression on first-line treatment in initially HER2-negative advanced gastric cancer (AGC) patients.Materials and Methods We enrolled 177 patients with baseline HER2-negative AGC and performed HER2 re-assessment after progression on first-line treatment from February 2012 to June 2016 at Asan Medical Center, Seoul, Korea. The re-assessed HER2 status was analyzed with baseline HER2 status and clinical characteristics.Results The median age was 54 years (range, 24 to 80 years), and 123 patients (69.5%) were men. Seven patients (4.0%) were HER2-positive on the re-assessment. Patients with baseline HER2 negativity confirmed by a single test (n=100) had a higher HER2-positive re-assessment rate compared to those who had repeated baseline testing (n=77) (5.0% vs. 2.6%). Among the patients with single baseline HER2 testing, the rate was higher in patients with baseline HER2 immunohistochemistry (IHC) 1+ compared to those with IHC 0 (13.4% vs. 3.6%).Conclusion Overall, 4.0% of patients with baseline HER2-negative AGC were HER2-positive on re-assessment, and the HER2-positive re-assessment rate was higher among patients who had a single test at baseline. HER2 re assessment may be considered for initially HER2-negative patients to determine their eligibility for HER2-directed therapy, particularly if their HER2 negativity was determined by a single test, especially if they had a single baseline HER2 IHC 1+ test.
참고문헌 (27)
- Siegel RL, "Cancer statistics, 2018", CA Can cer J Clin, 68, pp.7~30 (2018)
- Smyth EC, "Gastric cancer", Lancet, 396, pp.635~648 (2020)
- Nakamura Y, "Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers : an emerging paradigm", Nat Rev Clin Oncol, 18, pp.473~487 (2021)
- Bang YJ, "Trastuzumab in combination with chemo therapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- "Gastric cancer (version 2.2022)" (2022)[URL]
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Natu re, 513, pp.202~209 (2014)
- Van Cutsem E, "HER2 screening data from ToGA : targeting HER2 in gastric and gastroesophageal junction cancer", Gastric Cancer, 18, pp.476~484 (2015)
- Yagi S, "Clinical significance of intratumoral HER2 heteroge neity on trastuzumab efficacy using endoscopic biopsy speci mens in patients with advanced HER2 positive gastric cancer", Gastric Cancer, 22, pp.518~525 (2019)
- Tominaga N, "Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer", Gastric Cancer, 19, pp.553~560 (2016)
- Bartley AN, "HER2 testing and clinical decision making in gastroesophageal adenocarcinoma : gui deline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology", J Clin Oncol, 35, pp.446~464 (2017)
- Park SR, "Extra-gain of HER2-positive cases through HER2 reassess ment in primary and metastatic sites in advanced gastric can cer with initially HER2-negative primary tumours : Results of GASTric cancer HER2 reassessment study 1(GASTHER1)", Eur J Cancer, 53, pp.42~50 (2016)
- "R: A Language and Environment for Statistical Computing" (2021)[URL]
- Thuss-Patience PC, "Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocar cinoma(GATSBY) : an international randomised, open-label, adaptive, phase 2", 3 study, 2017, pp.18, 640~653
- Saeki H, "Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refrac tory to trastuzumab(KSCC1604)", Eur J Cancer, 105, pp.41~49 (2018)
- Pietrantonio F, "HER2 loss in HER2-positive gastric or gas troesophageal cancer after trastuzumab therapy : implication for further clinical research", Int J Cancer, 139, pp.2859~2864 (2016)
- Seo S, "Loss of HER2 positivity after anti-HER2 chemotherapy in HER2positive gastric cancer patients : results of the GASTric cancer HER2 reassessment study 3(GASTHER3)", Gastric Cancer, 22, pp.527~535 (2019)
- Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gas tric or gastro-oesophageal junction adenocarcinoma(RAIN BOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
- Shah MA, "Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously trea ted HER2-positive advanced gastric", gastroesophageal junc tion cancer, 2019, pp.22, 803~816
- Haffner I, "HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer : results from the prospective multicenter VARIANZ study", J Clin Oncol, 39, pp.1468~1478 (2021)
- Wakatsuki T, "Clinical impact of intratumoral HER2 heteroge neity on trastuzumab efficacy in patients with HER2-positive gastric cancer", J Gastroenterol, 53, pp.1186~1195 (2018)
- Bang K, "Association between HER2 heterogeneity and clinical out comes of HER2-positive gastric cancer patients treated with trastuzumab", Gastric Cancer, 25, pp.794~803 (2022)
- Shitara K, "Trastuzumab deruxtecan in previously treated HER2positive gastric cancer", N Engl J Med, 382, pp.2419~2430 (2020)
- Ogitani Y, "DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1", Clin Cancer Res, 22, pp.5097~5108 (2016)
- Ogitani Y, "Bystander killing effect of DS-8201a, a novel anti-human epi dermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 het erogeneity", Cancer Sci, 107, pp.1039~1046 (2016)
- Nishikawa K, "Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane-and trastu zumab-naive patients with HER2-positive, previously treat ed, advanced, or recurrent gastric cancer(JFMC45-1102)", Int J Cancer, 140, pp.188~196 (2017)
- Catenacci DV, "FIGHT : a randomized, double-blind, placebo-con trolled, phase II study of bemarituzumab(bema)combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric", gastroesophageal junction adenocarcinoma(GC), 2021, pp.39(15 Suppl), 4010~
- Sahin U, "FAST : a randomised phase II study of zolbetuxi mab(IMAB362)plus EOX versus EOX alone for first-line treatment of advanced CLDN18. 2-positive gastric and gastro oesophageal adenocarcinoma", Ann Oncol, 32, pp.609~619 (2021)